Amylyx Secures Funding for Therapy Candidate AMX0035

Amylyx Secures Funding for Therapy Candidate AMX0035

300443

Amylyx Secures Funding for Therapy Candidate AMX0035

Amylyx Pharmaceuticals has raised $135 million to advance the clinical development and the potential launch of its lead candidate AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). The Series C financing round, led by Viking Global Investors, also will be used to support further research and development of AMX0035 in other neurodegenerative diseases. “We have a clear mission at Amylyx: to develop new medications for ALS and other progressive neurodegenerative diseases,” James Frates, chief…

You must be logged in to read/download the full post.